BMS’ Breyanzi and Amgen’s Blincyto will now be available to patients in England with certain types of blood cancer.

UK health technology assessor the National Institute for Health and Care Excellence (NICE) has issued Final Draft Guidance ...

A case study on how DelveInsight supported a client with a focused CAR-TCR Summit coverage plan to gain exclusive insights into CAR-T therapies for B-cell malignancies.New York, USA, Feb. 21, 2025 (GL ...